Okada H, Yamazaki T, Takagi A, Murate T, Yamamoto K, Takamatsu J, Matsushita T, Naoe T, Kunishima S, Hamaguchi M, Saito H, Kojima T
Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
J Thromb Haemost. 2006 Sep;4(9):2003-9. doi: 10.1111/j.1538-7836.2006.02061.x.
To elucidate the molecular consequences of hereditary protein S (PS) deficiency, we investigated the in vitro synthesis of the PS missense mutants in COS-1 cells and their activated protein C (APC) cofactor activities.
Four patients with quantitative PS deficiency suffering from venous thrombosis were examined.
We identified three distinct novel missense mutations, R275C, P375Q and D455Y, and two previously reported missense mutations, C80Y and R314H. The P375Q and D455Y mutations were found in one patient and observed to be in linkage on the same allele. The R314H mutant showed the lowest level of expression (32.7%), and the C80Y, P375Q + D455Y, and R275C mutants exhibited a moderate impairment of expression, that is, 43.8%, 49.5%, and 72.3% of the wild type, respectively. Furthermore, pulse-chase experiments demonstrated that all mutants showed impaired secretion and longer half-lives in the cells than the wild type PS. In the APC cofactor assays, the C80Y mutant showed no cofactor activity, and the R275C mutant showed reduced activity, 62.3% of the wild type PS, whereas the R314H and P375Q + D455Y mutants exhibited normal cofactor activity.
These data indicate that the C80Y and R275C mutations affect the secretion and function of the PS molecule, and that the R314H and P375Q + D455Y mutations are responsible for only secretion defects, causing the phenotype of quantitative PS deficiency observed in the patients.
为阐明遗传性蛋白S(PS)缺乏的分子机制,我们研究了PS错义突变体在COS-1细胞中的体外合成及其活化蛋白C(APC)辅因子活性。
对4例患有静脉血栓形成的定量PS缺乏患者进行了检查。
我们鉴定出3种不同的新型错义突变,即R275C、P375Q和D455Y,以及2种先前报道的错义突变,即C80Y和R314H。在1例患者中发现了P375Q和D455Y突变,且观察到它们位于同一等位基因上呈连锁状态。R314H突变体表达水平最低(32.7%),而C80Y、P375Q + D455Y和R275C突变体表现出中度表达受损,分别为野生型的43.8%、49.5%和72.3%。此外,脉冲追踪实验表明,所有突变体与野生型PS相比,在细胞中分泌受损且半衰期更长。在APC辅因子活性测定中,C80Y突变体无辅因子活性,R275C突变体活性降低,为野生型PS的62.3%,而R314H和P375Q + D455Y突变体表现出正常的辅因子活性。
这些数据表明,C80Y和R275C突变影响PS分子的分泌和功能,而R314H和P375Q + D455Y突变仅导致分泌缺陷,从而引起患者中观察到的定量PS缺乏表型。